MedPath

Comparison of Focused and Radial Extracorporeal Shock Wave for Carpal Tunnel Syndrome

Not Applicable
Withdrawn
Conditions
Carpal Tunnel Syndrome
Interventions
Device: Extracorporeal shock wave
Registration Number
NCT03671473
Lead Sponsor
Tri-Service General Hospital
Brief Summary

Extracorporeal shock wave is a novel treatment for peripheral nerve entrapment. This study was designed to compare the efficacy of focused and radial extracorporeal shock wave for carpal tunnel syndrome.

Detailed Description

Both focused and radial extracorporeal shock wave had been proved to treat carpal tunnel syndrome by several studies. However, there was no study comparing these two methods. Considering different mechanisms and costs, this randomized comparative trial would be conducted to compare the efficacy of focused and radial extracorporeal shock wave for carpal tunnel syndrome.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Clinical and electrophysiological diagnosis of CTS
Exclusion Criteria
  • Cervical radiculopathy
  • Polyneuropathy
  • Brachial plexopathy
  • Thoracic outlet syndrome
  • Previous wrist surgery or steroid injection for CTS

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
FocusedExtracorporeal shock wavefESWT (0.05-0.29 mJ/mm2, 2000 shocks, 5 Hz)
RadialExtracorporeal shock waverESWT (2000shocks, 4 Bar, 5Hz)
Primary Outcome Measures
NameTimeMethod
Change from baseline of Boston Carpal Tunnel Syndrome Questionnaire (BCTQ) at 24th weeks after treatmentChange of the mean of total SSS and FSS from baseline at 24th weeks after treatment

Boston carpal tunnel syndrome questionnaire (BCTQ) is a frequently used patient-based questionnaire for measurement of carpal tunnel syndrome which encompasses two components. eleven questions and eight items were evaluated to rate the symptom severity scale (SSS) and functional status scale (FSS), respectively. Each question or item ranges from 1 to 5 with a higher score indicating severer symptom or a higher degree of disability. Total score of SSS ranges from 11-55 and FSS from 8-40. The mean of total SSS and FSS divided with each item score were used for further analysis.

Secondary Outcome Measures
NameTimeMethod
Cross-sectional area (CSA) of the median nervePre-treatment, 2nd, 4th, 8th, 12th and 24th weeks after treatment

Change from baseline in cross-sectional area of the median nerve on 2nd, 4th, 8th, 12th and 24th weeks after treatment.

Nerve conduction amplitudePre-treatment, 2nd, 4th, 8th, 12th and 24th weeks after treatment

Change from baseline in conduction amplitude of median nerve on 2nd, 4th, 8th,12th and 24th weeks after treatment.

Nerve conduction velocityPre-treatment, 2nd, 4th, 8th, 12th and 24th weeks after treatment

Change from baseline in conduction velocity of median nerve on 2nd, 4th, 8th,12th and 24th weeks after treatment.

Visual analogue scale (VAS)Pre-treatment, 2nd, 4th, 8th, 12th and 24th weeks after treatment

Digital pain severity or paresthesia/dysthesia within 1 week prior to evaluation was evaluated using visual analog scale (VAS). Pain score scale ranged from 0 to 10, with 10 indicating the most severe pain.

Trial Locations

Locations (1)

Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital

🇨🇳

Taipei, Neihu District, Taiwan

© Copyright 2025. All Rights Reserved by MedPath